Humana carries four consecutive earnings beats and 24% revenue growth, but severe operating margin deterioration has triggered value-trap flags, the stock trades above its near-term resistance level with an unfavorable risk/reward, and an unresolved legal disclosure adds a layer of uncertainty—leaving the setup unattractive for new exposure until the fundamental picture clarifies.
Thesis pillars
- Severe Margin Deterioration Value Trap→Stable
- Consistent Earnings Beat Streak→Stable
- Above Resistance Unfavorable Risk Reward→Stable
- +1 more pillar — see the Why tab for full reasoning
Humana Inc. (HUM) Stock Analysis
Breakout setup · Catalyst-Driven edge
Healthcare · Healthcare Plans
Sell if holding. Engine safety override at $399.00: Quality below floor (4.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10. Specifically: Below-average business quality.
Humana provides Medicare Advantage health plans, Medicaid managed care, and CenterWell primary care and pharmacy services, with Medicare representing 82.6% of Insurance segment premiums. In 2025, the company served approximately 15 million medical plan members; 83% of total... Read more
Sell if holding. Engine safety override at $399.00: Quality below floor (4.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10. Specifically: Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 65, MACD bullish. Score 5.1/10, moderate confidence.
Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 26d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About Humana Inc.
About Humana Inc.
Humana served approximately 15 million medical plan members at December 31, 2025, generating $123.8 billion in Insurance segment premiums and services revenue. Individual Medicare Advantage contributed $90.4 billion, or 70.3% of consolidated premiums and services revenue, while Total Medicare reached 82.6%. The company's CenterWell segment operated 350 primary care clinics and CenterWell Home Health across 37 states.
Humana earns revenue almost entirely from per-member-per-month payments from CMS for Medicare Advantage and Part D plans, supplemented by state Medicaid managed care contracts in Florida, Kentucky, Illinois, Indiana, Louisiana, Ohio, Oklahoma, South Carolina, Virginia, and Wisconsin. The 10-K discloses that approximately 93% of total premiums and services revenue came from federal and state government health care programs in 2025. Premium rates are set annually through CMS bid submissions and adjusted via a risk-adjustment model that pays more where member health status indicates higher expected costs — the company flags that inaccuracies in provider coding submitted to CMS expose it to Risk-Adjustment Data Validation audits. CenterWell's 350 primary care clinics and CenterWell Home Health generate additional revenue from external third-party payer and Medicare Advantage relationships. The company competes for Medicare enrollment during the annual October 15–December 7 enrollment window against large national insurers.
Show full overview
Florida concentrates 14% of consolidated premiums and services revenue in a single CMS contract cluster covering approximately 1.0 million individual Medicare Advantage members, a loss of which the 10-K characterizes as potentially material to results. Separately, Humana's Medicare Advantage plans experienced a significant decline in 4-star or higher Star Ratings for 2025, which the company has challenged through litigation. If that lawsuit fails, reduced quality bonus payments from CMS could weigh on 2026 revenues and trigger further membership attrition at the next annual enrollment period.
See also: Healthcare · Healthcare Plans
From Humana Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-07-05Recent Developments — Humana Inc.
Latest news
- NEWS UNH, Humana, CVS Soar, and Wall Street Analysts Take Note — benzinga Jul 4, 2026 positive
- NEWS Getting Wegovy Or Zepbound Through Medicare? Here's What Patients Need To Know Before Coverage Rolls Out Wednesday — benzinga Jun 30, 2026 neutral
- NEWS B of A Securities Maintains Neutral on Humana, Raises Price Target to $380 — benzinga Jun 24, 2026 positive
- NEWS Evercore ISI Group Maintains In-Line on Humana, Raises Price Target to $370 — benzinga Jun 11, 2026 positive
- NEWS Patients Denied Care, Then Approved Later? Federal Watchdog Raises Medicare Advantage Concerns — benzinga Jun 11, 2026 negative
Generated 2026-07-05T15:30:26Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $399.00: Quality below floor (4.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10. Specifically: Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 65, MACD bullish. Prior stop was $368.98. Score 5.1/10, moderate confidence.
Take-profit target: $406.70 (+2.5% upside). Prior stop was $368.98. Stop-loss: $368.98.
Target reached (-31.0% upside); Quality below floor (4.0 < 4.0); Value-trap signals (2/5): Margin compression (op margin -157.9%), Negative free cash flow.
Humana Inc. trades at a P/E of 42.4 (forward 25.2). TrendMatrix value score: 4.8/10. Verdict: Sell.
33 analysts cover HUM with a consensus score of 3.5/5. Average price target: $304.
What does Humana Inc. do?Humana provides Medicare Advantage health plans, Medicaid managed care, and CenterWell primary care and pharmacy...
Humana provides Medicare Advantage health plans, Medicaid managed care, and CenterWell primary care and pharmacy services, with Medicare representing 82.6% of Insurance segment premiums. In 2025, the company served approximately 15 million medical plan members; 83% of total premiums and services revenue came from federal government contracts. Florida alone accounts for 14% of consolidated premiums via individual Medicare Advantage.